ALEC
Alector, Inc. Common Stock
Nasdaq · usd
Alector, Inc. Common Stock (ALEC) trades at $1.91 (+4.10%) as of 2:22:10 PM EDT on Oct 26, 2026, -2.31% over the past month. Market cap is $204.33M, with 5.7 days to cover in short interest.
Stock performance
How Alector, Inc. Common Stock (ALEC) stock has performed from one day to one year, with its 52-week range.
- 1D
- +4.10%
- 1W
- -2.31%
- 1M
- -2.31%
- YTD
- +22.12%
- 1Y
- +27.00%
- 52-wk range
- $1.09 – $2.76
Key statistics
Today's trading snapshot for ALEC: day range, open, previous close, volume and market cap.
- Day range
- $1.85 – $1.94
- Open
- $1.85
- Prev close
- $1.83
- Volume
- 997.73K
- Market cap
- $204.33M
- Shares out
- 111.66M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Alector, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 14.74
- P/B
- -20.49
- P/FCF
- —
- ROE
- 1184.8%
- ROA
- -58.2%
- Debt/Equity
- -0.99
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Alector, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Underwriting agreementOct 16, 2026
On October 15, 2026, Alector, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC and BTIG, LLC relating to the issuance and sale of the Company's common stock. The Underwriting Agreement contains customary representations, warranties, conditions to closing, indemnification obligations and termination provisions.
- Executive compensation changeOct 14, 2026
The new exercise price for repriced options is $1.87 per share ... However, if an employee exercises a repriced Eligible Option before the end of the Retention Period ... such employee will be required to pay a premium exercise price that is equal to the original exercise price per share ... There was no change to the expiration dates or service-based vesting criteria of, or number of shares underlying the Eligible Options.
- Licensing agreementOct 5, 2026
On September 30, 2026, Alector provided notice of the exercise of its option to license certain patents from Spur Therapeutics Limited ... Under the Spur Agreement, Spur is granting Alector a worldwide, royalty-bearing, non-exclusive, transferable, sublicensable license under certain patents related to its engineered GCase.
- Clinical trial resultsJul 8, 2026
On April 29, 2026, the Company announced the discontinuation of the Phase 2 PROGRESS-AD trial of nivisnebart in individuals with early Alzheimer's disease following an interim futility analysis.
- Annual meeting resultsJun 17, 2026
On June 17, 2026, Alector, Inc. held its 2026 annual meeting of stockholders. At the Annual Meeting, Alector's stockholders voted on three proposals... The Class II director nominees were elected to serve until Alector's 2029 annual meeting of stockholders and until their successors are elected and qualified.
ALEC short interest
How heavily ALEC is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 5.7
- Short interest
- 6.15M
- Avg volume
- 1.07M
As of · reported to FINRA twice monthly.
ALEC news
The latest news and headlines about Alector, Inc. Common Stock (ALEC).
- Dementia Market Insight, Epidemiology, and Forecasts, 2022-2025 & 2026-2034positiveGlobeNewswire Inc.· Apr 13, 2026
- ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law FirmnegativeGlobeNewswire Inc.· Nov 26, 2025
- Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN TherapeuticnegativeGlobeNewswire Inc.· Oct 21, 2025
- Alector to Participate in Upcoming Healthcare ConferencespositiveGlobeNewswire Inc.· Feb 25, 2025
- Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025positiveGlobeNewswire Inc.· Jan 13, 2025
Frequently asked questions
What is the Alector, Inc. Common Stock (ALEC) stock price today?
Alector, Inc. Common Stock (ALEC) is trading at $1.91 (+4.10% on the day) as of 2:22:10 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Alector, Inc. Common Stock?
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for…
What is the short interest in ALEC?
As of Sep 30, 2026, ALEC has 6.15M shares short and 5.7 days to cover.
What exchange is ALEC listed on?
Alector, Inc. Common Stock (ALEC) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of ALEC with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ALEC analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.